Zealand Pharma A/S ZLDPF
Set alert
At close · Oct 30
- YTD
- -53.80%
- 1 year
- -53.55%
- Open
- 34.50
- Prev close
- 33.08
- Mkt cap
- 2.19B
- Vol
- 100
- Avg vol
- 520
- EPS
- 6.03
- P/E
- 5.49
More statistics
- Low
- 34.50
- High
- 34.50
- Earnings
- Aug 13, 2026
News
2 weeks ago defenseworld.net
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low – Time to Sell?
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) hit a new 52-week low during trading on Friday. The company traded as low as $34.00 and last traded at $34.00, with a volume of 2,132 shares…
1 month ago defenseworld.net
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price gapped down prior to trading on Thursday. The stock had previously closed at $41.99, but opened at $38.10. Zealand Pharma A/S shares…
1 month ago defenseworld.net
Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Hold” from Brokerages
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) has earned a consensus rating of "Hold" from the eleven analysts that are currently covering the company, MarketBeat reports. Nine research…
1 month ago reuters.com
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
Zealand Pharma received a positive opinion from the Committee for Medicinal Products for Human Use recommending approval of its drug candidate Zeydovio for the treatment of short bowel syndrome,…
2 months ago zacks.com
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year…
4 months ago benzinga.com
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.
4 months ago cnbc.com
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat…
4 months ago cnbc.com
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent…
4 months ago wsj.com
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
4 months ago marketwatch.com
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
Zealand Pharma lost a fifth of its market value on Monday after a late-stage trial found many patients stopped taking a weight-loss drug due to tolerability problems.
4 months ago reuters.com
Zealand Pharma shares drop 20% as obesity drug side effects raise concerns
Zealand Pharma's shares fell more than 20% in early trade on Monday after trial data showed its obesity drug survodutide had worse side effects and higher patient dropout rates than…
5 months ago zacks.com
Is Zealand Pharma AS (ZLDPF) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
5 months ago seekingalpha.com
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call Transcript
Zealand Pharma A/S (ZLDPY) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Zealand Pharma A/S (ZLDPF) Reports Q1 Loss, Lags Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to a loss of $0.67 per share a year ago.
5 months ago reuters.com
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Danish drug developer Zealand Pharma reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would…
6 months ago defenseworld.net
Comparing Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Zealand Pharma A/S (OTCMKTS:ZLDPF)
Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast…
7 months ago defenseworld.net
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat reports. Five…
7 months ago seekingalpha.com
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
8 months ago marketwatch.com
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
8 months ago wsj.com
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
8 months ago seekingalpha.com
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript
Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript